{"id":100,"date":"2019-05-17T10:41:31","date_gmt":"2019-05-17T10:41:31","guid":{"rendered":"https:\/\/www.ojaseyehospital.com\/blog\/?p=100"},"modified":"2023-12-12T12:49:36","modified_gmt":"2023-12-12T12:49:36","slug":"non-surgical-treatment-for-keratoconus-latest-advancement-with-eye-drops","status":"publish","type":"post","link":"https:\/\/www.ojaseyehospital.com\/blog\/non-surgical-treatment-for-keratoconus-latest-advancement-with-eye-drops\/","title":{"rendered":"Non surgical treatment for Keratoconus – latest advancement with eye drops"},"content":{"rendered":"\n

IVMED-80 (iVeena), which has received an orphan drug designation from the FDA. This  drug  has copper as an active ingredient, to enhance the activity of lysyl oxidase. Keratoconus<\/strong><\/a> occurs, Dr. Ambati explained, when there is a deficiency of natural crosslinks in the cornea, which is associated with lysyl oxidase mutations.<\/p>\n

Donor tissue that had been treated with IVMED-80 showed better stress-strain curves, Dr. Ambati said. In vivo rabbit studies with IVMED-80 showed increased ysyl oxidase activity, which he noted as biomechanical evidence of increased crosslinking. There have been no toxic or adverse events. Currently, a Phase 1\/2a clinical trial in Mexico is taking place with 36 keratoconus<\/strong><\/a> or post-LASIK ectasia patients who take two drops a day of either vehicle or IVMED-80. The primary end-point is reduction of kmax and kmean at 6 months with a secondary endpoint of biomechanical stiffness. At 1 month, 0.6 D of flattening seen at 1 year with the Dresden crosslinking protocol.<\/p>\n

A pharmacologic method of flattening the cornea, Dr. Ambati and should, perhaps, take more of Dr. Ambati’s focus. From a financial\/investment standpoint, Dr. Link said that this would be a relatively expensive project to do properly and the first quality investment would need to see detailed planning out to FDA approval.<\/p>\n\n

<\/blockquote>